Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. VitaNova Life Sciences's annualized net income for the quarter that ended in Apr. 2026 was $0.07 Mil. VitaNova Life Sciences's average shareholder tangible equity for the quarter that ended in Apr. 2026 was $1.95 Mil. Therefore, VitaNova Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Apr. 2026 was 3.69%.
The historical rank and industry rank for VitaNova Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
VNOV'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -10.53 Med: 13.21 Max: 57.4
Current: -1.88
During the past 10 years, VitaNova Life Sciences's highest Return-on-Tangible-Equity was 57.40%. The lowest was -10.53%. And the median was 13.21%.
VNOV's Return-on-Tangible-Equity is not ranked
in the Medical Distribution industry.
Industry Median: 8.755
vs VNOV: -1.88
VitaNova Life Sciences (OTCPK:VNOV) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
VitaNova Life Sciences Return-on-Tangible-Equity Related Terms
VitaNova Life Sciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for VitaNova Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VitaNova Life Sciences Return-on-Tangible-Equity Chart
VNOV vs HKPD, COSM, SNYR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, VitaNova Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.69% mean?
VitaNova Life Sciences (VNOV) has a Return-on-Tangible-Equity of 3.69% as of Apr. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on VitaNova Life Sciences and its competitors. This is 72% below median its historical median of 13.21.
Is VitaNova Life Sciences' Return-on-Tangible-Equity too high?
VitaNova Life Sciences' current Return-on-Tangible-Equity of 3.69% is 72% below median its 10-year median of 13.21. The Medical Distribution industry median Return-on-Tangible-Equity is 8.76. VitaNova Life Sciences' value of 3.69% is 57.9% below this industry median. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' Return-on-Tangible-Equity compare to HKPD and COSM?
VitaNova Life Sciences' Return-on-Tangible-Equity of 3.69% can be compared against companies in the Medical Distribution industry. The industry median Return-on-Tangible-Equity is 8.76. VitaNova Life Sciences' value of 3.69% is 57.9% below this benchmark. While the company's 10-year median is 13.21 vs. the industry median of 8.76, VitaNova Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.76, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current Return-on-Tangible-Equity of 3.69% is 57.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on VitaNova Life Sciences and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current Return-on-Tangible-Equity is 3.69%, which is 72% below median its own 10-year median of 13.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current Return-on-Tangible-Equity of 3.69%. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current Return-on-Tangible-Equity is 3.69%, which is 72% below median its 10-year median of 13.21 and 57.9% below the Medical Distribution industry median of 8.76. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current Return-on-Tangible-Equity is 3.69% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
Return-on-Tangible-Equity: 3.69% (72% below median its 10-year median of 13.21)
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 57.9% below the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
